ReviewClinical cancer research : an official journal of the American Association for Cancer Research2011
From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Trial
- Multiple Myeloma Cells Shift the Fate of Cytolytic ILC2s Towards TIGIT-Mediated Cell Death.Cancers · 2025Article
- [Progress in risk stratification and treatment of high-risk smoldering multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Review of whole-body magnetic resonance imaging in multiple myeloma.Japanese journal of radiology · 2024Review
- Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance.Blood cancer journal · 2024Article
- Efbalropendekin Alfa enhances human natural killer cell cytotoxicity against tumor cell linesFrontiers in immunology · 2024Article
- Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System.Pharmacoepidemiology and drug safety · 2023Article
- Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies.Cancers · 2023Article
- Review
- Novel immunotherapies in multiple myeloma.International journal of hematology · 2022Review
- Feasibility of artificial intelligence-supported assessment of bone marrow infiltration using dual-energy computed tomography in patients with evidence of monoclonal protein - a retrospective observational study.European radiology · 2022Observational
- Pathogenic signaling in multiple myeloma.Seminars in oncology · 2022Article
- Harnessing the Immune System to Fight Multiple Myeloma.Cancers · 2021Review
- Quantitative, DynamicDiagnostics (Basel, Switzerland) · 2021Article
- Therapeutic Strategies for Targeting IL-1 in Cancer.Cancers · 2021Review
- Review
- Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules.Blood advances · 2020Article
- Identifying monoclonal gammopathy of undetermined significance in electronic health data.Pharmacoepidemiology and drug safety · 2020Article
- Game of Bones: How Myeloma Manipulates Its Microenvironment.Frontiers in oncology · 2020Review
- Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.Molecules (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Since monoclonal gammopathy of undetermined significance (MGUS) was first described more than 30 years ago, the definition of the entity has evolved. Today, 3 distinct clinical MGUS subtypes have been defined: non-immunoglobulin M (IgM; IgG or IgA) MGUS, IgM MGUS, and light chain MGUS. Each clinical MGUS subtype is characterized by unique intermediate stages and progression events. Although we now have strong evidence that multiple myeloma is consistently preceded by a precursor state at the molecular level, there is urgent need to better understand mechanisms that regulate transformation from precursor to full-blown multiple myeloma. In the future, if such knowledge was available, it would allow clinicians to define high-risk and low-risk precursor patients for a more tailored clinical management. Also, it would provide insights on the individual patient's disease biology, which, in turn, can be used for targeted and more individualized treatment strategies. On the basis of current clinical guidelines, patients diagnosed with MGUS and smoldering myeloma should not be treated outside of clinical trials. In the near future, it seems reasonable to believe that high-risk precursor patients will likely become candidates for early treatment strategies. In this review, we discuss novel insights from recent studies and propose future directions of relevance for clinical management and research studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.